SEC Form 4 · accession 0001562180-15-000603
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jodie Pope Morrison
Officer — President and CEO · Director
Period of report
Jul 22, 2015
Accepted (ET)
Jul 24, 2015 · 4:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 22, 2015 | M | 2,574 | $2.31 | A | 12,125 | D | |
| Common Stock | Jul 22, 2015 | M | 7,426 | $0.63 | A | 19,551 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.31 | Jul 22, 2015 | M | 2,574 | D | — | May 1, 2018 | Common Stock | 2,574 | 0 | D |
| Stock Option (right to buy)F1 | $0.63 | Jul 22, 2015 | M | 7,426 | D | — | May 5, 2019 | Common Stock | 7,426 | 15,015 | D |
Explanation of responses
- F1This option is fully vested.